Showing results (131-140 of 157) with videos related to
Sort By:
Pageof 16
The British Journal of Dermatology|February 22, 2011
Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studiesK Reich, R G Langley, M Lebwohl, et al.Journal of Psoriasis and Psoriatic Arthritis|September 19, 2024
The Disease Burden of Generalized Pustular Psoriasis: Real-World Evidence From CorEvitas' Psoriasis RegistryM Lebwohl, R A Medeiros, R H Mackey, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|December 20, 2023
Efficacy and safety of tirbanibulin 1% ointment in actinic keratoses: Data from two phase-III trials and the real-life clinical practice presented at the European Academy of Dermatology and Venereology Congress 2022G Pellacani, T Schlesinger, N Bhatia, et al.Acta Dermato-Venereologica|July 20, 2002
A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgarisW S Douglas, Y Poulin, J Decroix, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|July 13, 2021
Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysisK Reich, U Mrowietz, A Menter, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|May 5, 2020
Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY)J Bagel, A Blauvelt, J Nia, et al.The British Journal of Dermatology|September 12, 2015
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)C Paul, J Cather, M Gooderham, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|February 13, 2017
Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasisA Blauvelt, K A Papp, H Sofen, et al.The British Journal of Dermatology|April 12, 2019
Continued treatment with secukinumab is associated with high retention or regain of responseM Augustin, D Thaci, K Eyerich, et al.The British Journal of Dermatology|June 13, 2020
Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studiesA Blauvelt, C Paul, P van de Kerkhof, et al.Pageof 16